Deconstructing Obstructive Sleep Apnea with Reena Mehra, MD, MS

Podcast

The Cleveland Clinic Director of Sleep Disorders Research navigates the complexities of OSA presentation, progression, management and eradication with the Lungcast team.

Episode highlights

0:16 The origin of sleep apnea diagnosis
1:48 Current sleep apnea burden in the US
3:16 Defining obstructive sleep apnea
4:40 The OSA pathophysiology
8:36 Clinical characteristics of OSA
11:16 Role of head and neck anatomy
12:30 Pros and cons of home sleep studies and polysomnography
16:11 Benefit of the Apnea-Hypopnea Index
21:55 The interplay of cardiovascular disease
23:41 The importance of PAP adherence
28:35 Addressing daytime somnolence
32:36 Additional OSA therapy options
35:55 How much weight should patients lose?
36:39 Future diagnosis and treatment
38:25 Outro

Obstructive sleep apnea (OSA) is simultaneously a greatly under-acknowledged and significantly impactful condition in the US. As rates of obesity, chronic pulmonary and cardiovascular disease still climb among US adults, the common sleep disorder has become more prominent and burdensome—despite there being clear lines of diagnosis and care.

This month’s episode of Lungcast delves into the characteristics, pathophysiology and comorbid impacts of OSA, before reviewing the resources available to detect and lessen its effects—or even eradicate it.

American Lung Association (ALA) chief medical officer Albert Rizzo, MD, interviews Reena Mehra, MD, MS, professor of medicine and director of Sleep Disorders Research at the Cleveland Clinic, on the intricate state of OSA in the US.

Along with learning from Mehra about her colleagues’ work in advancing the field of sleep apnea treatment and diagnoses, Rizzo reviews the very origin of the disease, and reflects on his own experiences in managing uniquely-presenting patients.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:

Related Videos
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
© 2024 MJH Life Sciences

All rights reserved.